Industry Satellite Symposia

This symposium is organised and entirely funded by Vertex Pharmaceuticals.

Due to pharmaceutical industry regulations, this symposium is for healthcare professionals (HCPs) and scientific professionals only, it is not open to patients or members of the public.

Thursday 5 June 2025

13:00–14:00 CEST

Coral 2&3, Level 2,
Allianz MiCo,
Milan, Italy

Expanding CFTR-based treatment for people with CF

Objectives:

  • Discuss the recent advances in understanding of CFTR science through clinical trials and real-world studies
  • Highlight the relationship between restoration of CFTR function to normal levels and improved clinical outcomes
  • Discuss the continued progress and effort with genetic therapies

Chaired by:
Prof. Jane Davies, Imperial College London, UK 

Panellists:     
Prof Isabelle Fajac, AP-HP Université Paris Cité, Paris, France
Dr Simon Gräber, Charité- Universitätsmedizin Berlin, Germany
Dr Fred Van Goor, Vice President, Cystic Fibrosis Research, Vertex Pharmaceuticals, USA

13:00–13:15

Chair’s opening remarks:
The CF care journey continues

Prof. Jane Davies

13:15–13:30

Review the recent advances in understanding
CFTR science

Prof. Jane Davies

13:30–13:45

Measurements of CFTR function and relationship with clinical outcomes
Approaches to assessing response to CFTR modulation

Prof Isabelle Fajac and
Dr Simon Gräber

13:45–13:55

Discuss the continued progress and effort with genetic therapies

Prof. Jane Davies

13:55–14:00

Chair’s closing remarks

Prof. Jane Davies  

Questions and comments from the audience is encouraged throughout the symposium.

Friday 6 June 2025

Coral 2&3, Level 2 

Allianz MiCo
Milan, Italy

Digging deeper into DPP1 (CatC) and its role in the shared pathophysiology of non-CF and CF bronchiectasis
Boehringer Ingelheim Breakfast Session at ECFS 2025
Co-chairs: James Chalmers and Marcus Mall
Time (CEST) Presentation title Presenter
08:00-08:03 Welcome and introduction James Chalmers
08:03-08:23 A case of shared pathophysiology: neutrophilic inflammation and the vicious vortex in non-CF and
CF bronchiectasis
James Chalmers
08:23-08:43 Investigating the role of DPP1 (CatC) in CF bronchiectasis Marcus Mall
08:43-08:45 Final remarks and meeting close Marcus Mall

This symposium is organised and entirely funded by Vertex Pharmaceuticals.

Due to pharmaceutical industry regulations, this symposium is for healthcare professionals (HCPs) and scientific professionals only, it is not open to patients or members of the public.

Friday 6 June 2025

13:00–14:00 CEST

Coral 2&3, Level 2,
Allianz MiCo,
Milan, Italy

Unmet needs and clinical challenges in the CFTR modulator era

Objectives:

  • Address the remaining needs in the CF community, focussing on pwCF living longer in the CFTRm era
  • Discuss the emerging clinical needs in pwCF despite on CFTRm (early and late starters on CFTRm), their treatment goals and how these may be overcome through improvement of CFTR function towards normal levels  
  • Consider the important role of MDTs in supporting the ageing CF population

Chaired by:

Prof Francesco Blasi, IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy

Speakers:     

Dr Gwyneth Davies, University College London, London, UK
Prof Andrea Gramegna, IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy
Dr Sarah Collins, Royal Brompton and Harefield Hospitals, London, UK

13:00–13:10

Chair’s opening remarks:
What does the future look like for people with CF?

Prof Francesco Blasi

13:10–13:25

Addressing the clinical needs in pwCF who initiate early onto CFTRm

Dr Gwyneth Davies

13:25–13:40

Addressing the clinical needs in pwCF who start late on CFTRm with established disease

Prof Andrea Gramegna

13:40-13:50

Ageing with CF: The supporting role of the MDTs

Dr Sarah Collins

13:55–14:00

Chair’s closing remarks

Prof Francesco Blasi


Questions and comments from the audience is encouraged throughout the symposium.

The 48th European Cystic Fibrosis Conference has been assessed as compliant by EthicalMedTech.
Please view the assessment details: click here